About Horizon Therapeutics (NASDAQ:HPTX)
Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company's products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company's products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity21.30%
Return on Assets15.42%
Horizon Therapeutics (NASDAQ:HPTX) Frequently Asked Questions
What is Horizon Therapeutics' stock symbol?
Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HPTX."
How were Horizon Therapeutics' earnings last quarter?
Horizon Therapeutics Inc (NASDAQ:HPTX) announced its earnings results on Thursday, February, 26th. The biopharmaceutical company reported $0.47 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.67. The biopharmaceutical company had revenue of $30.80 million for the quarter, compared to the consensus estimate of $24.60 million. Horizon Therapeutics had a return on equity of 21.30% and a net margin of 23.13%. Horizon Therapeutics's revenue was up 65.6% compared to the same quarter last year. View Horizon Therapeutics' Earnings History.
Has Horizon Therapeutics been receiving favorable news coverage?
Press coverage about HPTX stock has trended somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Horizon Therapeutics earned a media sentiment score of 0.11 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 47.48 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Horizon Therapeutics?
Shares of HPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Horizon Therapeutics' stock price today?
One share of HPTX stock can currently be purchased for approximately $45.99.
How big of a company is Horizon Therapeutics?
Horizon Therapeutics has a market capitalization of $964.29 million.
How can I contact Horizon Therapeutics?
Horizon Therapeutics' mailing address is 2000 Sierra Point Pkwy Ste 400, BRISBANE, CA 94005-1849, United States. The biopharmaceutical company can be reached via phone at +1-650-7457802.
MarketBeat Community Rating for Horizon Therapeutics (HPTX)MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics and other stocks. Vote "Outperform" if you believe HPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Horizon Therapeutics (NASDAQ:HPTX) Analyst Ratings History
(Data available from 4/26/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Horizon Therapeutics (NASDAQ:HPTX) Earnings History and Estimates Chart
Horizon Therapeutics (NASDAQ HPTX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/26/2015||Q414||($0.20)||$0.47||$24.60 million||$30.80 million||View||N/A|
|11/6/2014||Q3 2014||($0.05)||($0.06)||$24.74 million||$26.20 million||View||N/A|
|8/7/2014||Q2||($0.18)||$0.89||$22.00 million||$37.10 million||View||N/A|
|5/6/2014||Q1 2014||($0.01)||$0.12||$17.00 million||$19.48 million||View||N/A|
|2/27/2014||Q4 2013||$0.03||$0.13||$15.75 million||$18.63 million||View||N/A|
|11/12/2013||Q3 2013||($0.08)||$0.10||$12.60 million||$15.49 million||View||N/A|
|8/14/2013||Q2 2013||($0.17)||($0.22)||$2.17 million||$7.30 million||View||N/A|
|5/9/2013||Q1 2013||($0.67)||($0.52)||$0.50 million||$0.78 million||View||N/A|
Horizon Therapeutics (NASDAQ:HPTX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Horizon Therapeutics (NASDAQ HPTX) Insider Trading and Institutional Ownership History
Horizon Therapeutics (NASDAQ HPTX) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/17/2015||Christine A Nash||SVP||Sell||10,000||$37.56||$375,600.00|| |
|3/10/2015||Christine A Nash||SVP||Sell||9,900||$29.63||$293,337.00|| |
|1/20/2015||Christine A Nash||SVP||Sell||5,000||$24.82||$124,100.00|| |
|6/6/2014||Scott D Sandell||Major Shareholder||Sell||1,430||$5.54||$7,922.20|| |
|3/4/2014||James Healy||Director||Sell||23,625||$30.02||$709,222.50|| |
|1/14/2014||Christine Nash||SVP||Sell||10,000||$24.09||$240,900.00||5,098|| |
|9/20/2013||Highland Management Partners V||major shareholder||Sell||5,754||$25.84||$148,683.36|| |
|9/18/2013||Highland Management Partners V||major shareholder||Sell||15,544||$26.00||$404,144.00|| |
|9/16/2013||Highland Management Partners V||major shareholder||Sell||8,300||$26.29||$218,207.00|| |
|9/11/2013||Highland Management Partners V||Major Shareholder||Sell||34,573||$26.56||$918,258.88|| |
|9/9/2013||Highland Management Partners V||Major Shareholder||Sell||18,048||$26.06||$470,330.88|| |
|8/5/2013||Highland Management Partners V||major shareholder||Sell||25,000||$25.48||$637,000.00|| |
|8/2/2013||Highland Management Partners V||Major Shareholder||Sell||47,245||$25.35||$1,197,660.75|| |
|5/30/2013||Bay City Capital Llc||Major Shareholder||Sell||17,366||$21.06||$365,727.96|| |
|5/20/2013||Bay City Capital Llc||Major Shareholder||Sell||131,455||$22.68||$2,981,399.40|| |
Horizon Therapeutics (NASDAQ HPTX) News Headlines
Horizon Therapeutics (NASDAQ:HPTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Horizon Therapeutics (NASDAQ:HPTX) Income Statement, Balance Sheet and Cash Flow Statement
Horizon Therapeutics (NASDAQ HPTX) Stock Chart for Thursday, April, 26, 2018